Centaurus Biopharma Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

China National Petroleum Corporation

Cnpc Bohai Equipment Manufacturing Co., Ltd.

Shulong Wang

Yuandong Hu

Xijie Liu

Yong Peng

Yongxin Han

Hong Luo

Hui Zhang

Xiquan Zhang

Hongjiang Xu

Na Zhao

Dengming Xiao

Gen Li

Bo Liu

Wei Wu

Zhihua Liu

Yu Shen

Sheng Zhao

Liang Cheng

Xin Tian

Shanchun Wang

Honghao Yu

Xinhe Xu

Yin Wang

Mei Liu

Fang Gu

Yongqing Shi

Hongguang Zhang

Xiaolin Wang

Xianying Tan

Jia Tang

Chonglong Li

Lipeng Zhang

Kuncheng Chen

Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers. 

1,3,5-triazine derivative and method of using same

The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect. 

Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof

The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers. 

Antitumor compound targeting IDH2 mutation and method of use thereof

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.

2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors

The disclosure relates to liquid nitrogen pump equipment load testing and experimenting apparatus, and testing and experimenting method thereof, used for oil-gas fields or coalbed methane nitrogen foam fracturing equipment testing. A hydraulic damping apparatus unit and a pressure regulation unit are provided; the hydro-mechanical damping apparatus unit comprises a water tank, a pump unit apparatus, and a pipe manifold system connected in sequence.

Liquid nitrogen pump equipment load testing and experimenting apparatus and testing and experimenting method thereof

Growing community of inventors

Beijing, China

Shulong Wang